Amdocs (NASDAQ:DOX - Get Free Report) had its price objective lowered by research analysts at Stifel Nicolaus from $71.00 to $46.00 in a note issued to investors on Wednesday, Benzinga reports. The brokerage currently has a "buy" rating on the technology company's stock. Stifel Nicolaus's price target points to a potential downside of 26.32% from the company's previous close.
A number of other brokerages also recently issued reports on DOX. Weiss Ratings upgraded Amdocs from a "sell (d+)" rating to a "hold (c-)" rating in a report on Friday, October 23rd. Wall Street Zen upgraded Amdocs from a "hold" rating to a "buy" rating in a report on Saturday, August 29th. Finally, Oppenheimer lowered Amdocs from an "outperform" rating to a "market perform" rating in a research report on Wednesday. Three investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $78.33.
View Our Latest Stock Analysis on DOX
Amdocs Trading Down 1.7%
Shares of DOX opened at $62.43 on Wednesday. The stock has a market capitalization of $6.74 billion, a P/E ratio of 9.88, a PEG ratio of 1.01 and a beta of 0.42. Amdocs has a twelve month low of $49.74 and a twelve month high of $85.63. The company has a quick ratio of 0.94, a current ratio of 0.94 and a debt-to-equity ratio of 0.23. The firm has a fifty day simple moving average of $60.65 and a two-hundred day simple moving average of $62.58.
Amdocs (NASDAQ:DOX - Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The technology company reported $1.98 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $1.98. The firm had revenue of $1.19 billion for the quarter, compared to analysts' expectations of $1.19 billion. Amdocs had a net margin of 9.75% and a return on equity of 20.28%. The company's revenue for the quarter was up 3.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.83 earnings per share. On average, research analysts anticipate that Amdocs will post 6.57 EPS for the current year.
Hedge Funds Weigh In On Amdocs
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Alpine Bank Wealth Management lifted its stake in shares of Amdocs by 58.2% in the third quarter. Alpine Bank Wealth Management now owns 500 shares of the technology company's stock worth $29,000 after buying an additional 184 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Amdocs during the third quarter valued at approximately $57,000. Versant Capital Management Inc increased its position in shares of Amdocs by 3,340.6% during the third quarter. Versant Capital Management Inc now owns 1,101 shares of the technology company's stock valued at $63,000 after acquiring an additional 1,069 shares in the last quarter. Farther Finance Advisors LLC raised its holdings in Amdocs by 16.4% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,292 shares of the technology company's stock worth $74,000 after acquiring an additional 182 shares during the last quarter. Finally, GAMMA Investing LLC raised its holdings in Amdocs by 65.7% in the 2nd quarter. GAMMA Investing LLC now owns 1,725 shares of the technology company's stock worth $87,000 after acquiring an additional 684 shares during the last quarter. Hedge funds and other institutional investors own 92.02% of the company's stock.
Amdocs News Summary
Here are the key news stories impacting Amdocs this week:
- Positive Sentiment: Amdocs expanded its collaboration with AT&T on AI-enabled operations modernization, offering a potential opportunity to deepen business with a major telecom customer. AT&T and Amdocs Expand Collaboration
- Positive Sentiment: The company declared a quarterly dividend of $0.569 per share, equivalent to an annualized $2.28. Amdocs dividend announcement
- Neutral Sentiment: Amdocs agreed to acquire insurance technology company EIS for $340 million, giving it a potential entry into a new market, though the deal adds execution and integration considerations. Amdocs acquires EIS
- Neutral Sentiment: Fiscal fourth-quarter adjusted EPS of $1.98 and revenue of $1.19 billion matched estimates; revenue grew 3.8% year over year. The in-line results offered little offset to concerns about the forward outlook. Amdocs Q4 earnings flash
- Negative Sentiment: A dispute with T-Mobile is clouding Amdocs’ outlook. The company cut its fiscal 2027 revenue guidance, and the CEO declined to detail the company’s revenue exposure to T-Mobile, leaving investors uncertain about the potential scale of the impact. Amdocs CEO declines to detail T-Mobile exposure
- Negative Sentiment: Oppenheimer downgraded Amdocs to Perform, adding to the cautious tone around the lowered outlook and customer dispute. Oppenheimer downgrades Amdocs
About Amdocs
(
Get Free Report)
Amdocs Ltd. NASDAQ: DOX is a global provider of software and technology services for communications, media and entertainment companies. Its solutions help service providers manage customer relationships, billing, subscriptions, product offerings and digital experiences across consumer and enterprise markets.
The company's portfolio includes business support systems and operational support systems, cloud-based software, artificial intelligence and automation tools, network and service management platforms, and solutions for media distribution and monetization.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Amdocs, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amdocs wasn't on the list.
While Amdocs currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.